No Data
No Data
IGM to Slash 73% of Workforce, Halt Two Drug Programs
Vir Biotech Upgraded at Morgan Stanley on Cancer Drug Data
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
Sanofi (SNY.US) announced that the anti-CD38 monoclonal antibody has been approved in China for the treatment of multiple myeloma.
Sanofi (SNY.US) has just announced that the injection of Aishetuximab has been approved by China's National Medical Products Administration (NMPA) for market launch.
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies